摘要
目的:观察莫西沙星联合比阿培南治疗重症肺炎患者的效果。方法:选取2021年6月至2023年6月该院收治的104例重症肺炎患者进行前瞻性研究,按随机数字表法将其分为研究组与对照组各52例。对照组予以比阿培南治疗,研究组在对照组基础上联合莫西沙星治疗。比较两组临床疗效,治疗前后炎性因子[白细胞介素(IL)-1β、IL-18]水平、呼吸功能指标[氧合指数(OI)、肺动态顺应性(Cdyn)、呼吸做功(WOB)]水平,以及不良反应发生率。结果:研究组治疗总有效率为94.23%(49/52),高于对照组的76.92%(40/52),差异有统计学意义(P<0.05);治疗后,两组IL-1β、IL-18水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组OI、Cdyn水平均高于治疗前,且研究组高于对照组,两组WOB均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P<0.05)。结论:莫西沙星联合比阿培南治疗重症肺炎患者可提高治疗总有效率,改善呼吸功能指标水平,降低炎性因子水平,其效果优于单纯比阿培南治疗。
Objective:To observe effects of Moxifloxacin combined with Biapenem in treatment of patients with severe pneumonia.Methods:A prospective study was conducted on 104 patients with severe pneumonia admitted to the hospital from June 2021 to June 2023.According to the random number table method,they were divided into study group and control group,52 cases in each group.The control group was treated with Biapenem,while the study group was treated with Moxifloxacin on the basis of that of the control group.The clinical efficacy,the levels of inflammatory factors[interleukin(IL)-1β,IL-18]and respiratory function indexes[oxygenation index(OI),dynamic compliance(Cdyn),respiratory work(WOB)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 94.23%(49/52),which was higher than 76.92%(40/52)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of IL-1βand IL-18 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of OI and Cdyn in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the WOB of the two groups was lower than that before the treatment,and that in the study group was lower than that in the control group;and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P<0.05).Conclusions:Moxifloxacin combined with Biapenem in the treatment of the patients with severe pneumonia can improve the total effective rate of treatment,improve the levels of respiratory function indicators,and reduce the levels of inflammatory factors.Moreover,it is superior to simple Biapenem treatment.
作者
雷建富
LEI Jianfu(Department of Pharmacy of Xinyang People’s Hospital,Xinyang 464000 Henan,China)
出处
《中国民康医学》
2024年第14期31-33,共3页
Medical Journal of Chinese People’s Health
关键词
重症肺炎
莫西沙星
比阿培南
炎性因子
呼吸功能
不良反应
Severe pneumonia
Moxifloxacin
Biapenem
Inflammatory factor
Respiratory function
Adverse reaction
